Study Finds Variations in Percentage of Clinical Teams Using Simple and Complex Adaptive Trial Designs
04. September 2017 19:16 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - September 04, 2017) - Recent analysis of clinical development teams show that surveyed clinical teams are divided on whether or not companies should...
Clinical Teams From Top Pharma Companies Are Overcoming Challenges in Planning and Implementing Adaptive Trial Design Studies
19. Juli 2017 19:23 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2017) - A recent study of Top 10, Top 50, and small medical device companies found that addressing regulators' concerns for late-stage studies is...
Centralized Adaptive Trial Design Teams Facilitate Communication Between Global & Country-Level Pharma Teams
22. Juni 2017 15:41 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 22, 2017) - The majority of surveyed clinical trial teams -- from those with global responsibility to those positioned at the country level -- report...
Adaptive Design Trials Emerge As Most Popular Method Used By Pharma Companies to Reduce Phase 3 Failures
07. Juni 2017 16:27 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 07, 2017) - About 60% of surveyed life science teams believe that using adaptive design trials in early-stage clinical studies increase the odds of...
Study Finds Variations in Percentage of Clinical Teams Using Adaptive Trials and When
11. Mai 2017 20:00 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 11, 2017) - There is no one-size-fits-all approach to strategic adaptive trial design use, according a study published by business intelligence firm...
Surveyed Top 50 Pharma and Biotech Companies Report Average Per-Patient Costs of $57,500 During Non-Adaptive Phase 1 Studies
27. März 2017 19:28 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - March 27, 2017) - Surveyed pharmaceutical, biotech, and device companies expend up to $120,000 per patient during Phase 1 non-adaptive studies, according to...
Centralized Adaptive Trial Design Teams Promote Cross-Geography Communication
07. Dezember 2016 08:36 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - December 07, 2016) - A recent study released by Cutting Edge Information found that most surveyed clinical trial teams -- either global or at the country...
The #1 Strategic Method Drug Companies Use to Increase the Odds of Phase 3 Success
15. November 2016 08:17 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - November 15, 2016) - A new study published by Cutting Edge Information found that 60% of surveyed life science teams agreed that risk of phase 3 failures...